Morphic Therapeutic (MORF) PT Raised to 'Street High' $111 at BMO Capital

March 1, 2021 3:55 PM EST
Get Alerts MORF Hot Sheet
Price: $54.54 -1.55%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

BMO Capital analyst Do Kim raised the price target on Morphic Therapeutic (NASDAQ: MORF) to a "Street High" $111.00 (from $40.00) while maintaining an Outperform rating.

The analyst commented, "We raise our target price to $111 from $40, following highly positive receptor occupancy (RO) data from MORF-057 SAD Phase 1, as we increase our peak sales estimate to $4.4B (from $3.1B) and our probability of success to 55% (from 35%). We believe the >95% RO achieved by the three highest MORF-057 dose cohorts provides proof-of-mechanism for α4β7 inhibition, an approach well-validated by Entyvio for IBD. With Entyvio-like efficacy and clean safety, oral MORF-057 could be preferred over injectable biologics in IBD, which is a $20B market opportunity."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

BMO Capital